Hong Kong Stock Movement | Heng Rui Medicine (01276.HK) rose more than 4% in late trading as Chinas first anti-HER2 product for colorectal cancer was approved for market launch.

According to Zhithong Finance APP, Heng Rui Medicine (01276.HK) rose over 4% in late trading and, as of this writing, is up 3.9%, priced at HKD 58.6, with a transaction volume of HKD 220 million.